One of the names we like a lot right now is [TICKER: SNY ] Sanofi . This is a company that has a strong entrenchment in ..... advantage, another moat source for the firm. [TICKER: SNY ] Sanofi we think is very well-positioned for growth over the
pharmaceutical companies, Sanofi SNY benefits from patent protection ..... cost of capital. Also, Sanofi 's unique entrenched position ..... cost insulin production. Sanofi 's existing product line ..... biologic markets exposes Sanofi to less-pronounced generic
Regeneron ( REGN +0.1% ) and development partner Sanofi ( SNY +0.8% ) report encouraging Phase 2b results for their investigational mAb dupilumab as a treatment for adults with moderate
combined. On July 1st, 2014, French drugmaker Sanofi ( SNY ) increased its stake in Regeneron ..... 5% in April and 16% in 2013. Sanofi has expressed interest and received ..... long-standing relationship with Sanofi , the fifth-largest pharmaceutical
Abasria, a direct competitor to its top-selling Lantus , Sanofi ( SNY -0.7% ) files a patent infringement suit in the U ..... It will come off patent in February 2015. The filing of Sanofi 's original lawsuit triggered the automatic 30-month
(Reuters) - Sanofi SA , whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it.
July 8 (Reuters) - Sanofi SA , whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and...
The U.S. regulator accepts Sanofi 's ( SNY -0.3% ) NDA for its investigational basal insulin Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL). The
July 1 (Reuters) - French drugmaker Sanofi SA will raise its stake in Regeneron Pharmaceuticals Inc to 22.5 percent, Sanofi said in a U.S. regulatory filing Tuesday, as part of an agreement between...
DUBAI, June 26 (Reuters) - French drugmaker Sanofi is leading an investor group buying a 66 percent stake in the Globalpharma unit of Dubai Investments, the Gulf-based diversified investment group said on Thursday.